LUNG Pulmonx Corporation

1.840USD+3.37%Mkt Cap: 77.72M $P/E: —

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobr…

Key Statistics

Company
Market Cap77.72M USD
Enterprise Value76.82M USD
Revenue (TTM)87.44M USD
Gross Profit67.14M USD
Net Income (TTM)-54.00M USD
Revenue/Share2.10 USD
Last Price1.840 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees296
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.89
PEG—
EV/EBITDA-1.69
EV/Revenue0.88
P/S0.86
P/B1.95
EPS (TTM)-1.15
EPS (Forward)-0.94
52W Range
1.13040% of range2.890
52W High2.890 USD
52W Low1.130 USD
Profitability
Gross Margin74.19%
Oper. Margin-39.80%
EBITDA Margin-52.02%
Profit Margin-59.67%
ROE-99.79%
ROA-41.77%
Growth
Revenue Growth-4.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-32.38M USD
CapEx (TTM)452.00K USD
FCF Margin-13.43%
FCF Yield-15.11%
Net Debt368.00K USD
Net Debt/EBITDA-0.01
Balance Sheet
Debt/Equity1.04
Current Ratio4.32
Quick Ratio3.36
Book Value/Sh0.91 USD
Cash/Share1.30 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)3.400 USD
Upside (mean)+84.8%
Target Range2.500 USD – 5.000 USD
2.500+84.8% to mean5.000
# Analysts5
Ownership
Shares Out.42.24M
Float37.61M
Insiders4.64%
Institutions62.81%
Short Interest
Short Ratio2.3d
Short % Float2.34%
Short % Out.1.97%
Shares Short847.84K
Short (prev mo.)1.07M
Technical
SMA 502.048 (-10.2%)
SMA 2001.679 (+9.6%)
Beta0.34
S&P 52W Chg16.45%
Avg Vol (30d)310.15K
Avg Vol (10d)215.08K
Technical Indicators
RSI (14)44.4
MACD-0.0450
MACD Signal-0.0211
MACD Hist.-0.0240
BB Upper2.100 USD
BB Middle1.933 USD
BB Lower1.766 USD
BB Width17.33%
ATR (14)0.1371 USD
Vol Ratio (20d)1.42x